Zenas BioPharma, Inc.
ZBIO · XNASCIK 1953926fmd_1BB1D0GCG0HBXX7SJRGG5B5YKMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 50 | 5 | 10 |
| Research and development | 60 | 139 | 168 |
| Total operating expenses | 87 | 169 | 393 |
| Operating income | (37) | (164) | (383) |
| Interest expense | – | – | 7 |
| Interest and investment income | – | 8 | 12 |
| Other non-operating income (expense) | 0 | 7 | 5 |
| Income before taxes | (37) | (157) | (378) |
| Income tax expense | 0 | 0 | (0) |
| Net income from continuing operations | (37) | (157) | (378) |
| Net income | (37) | (157) | (378) |